Experts from Stoke are consulted for input to inform news coverage about our innovative science, the serious diseases we are working to address, and the industry we are proud to be a part of.
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome